Voyager Therapeutics Announces Licensing Agreement With Pfizer To Develop Gene Therapies

Voyager Therapeutics, Inc. (VYGR) on Wednesday announced a licensing agreement with Pfizer for Voyager's TRACER AAV Capsids to develop gene therapies for certain neurologic and cardiovascular diseases.

The deal gives Pfizer the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager's TRACER ((Tropism Redirection of AAV by Cell-type-specific Expression of RNA)) platform, and to license capsids for exclusive use in Pfizer's development of AAV gene therapies incorporating two undisclosed transgenes.

Voyager will receive $30 million as upfront payment and is eligible for up to $20 million in exercise fees for two options, exercisable by Pfizer within 12 months of signing.

In addition, Voyager is entitled to get up to $580 million on reaching certain targets associated with licensed products incorporating the two undisclosed Pfizer transgenes together with a Voyager licensed capsid. Voyager is also eligible to receive mid- to high-single-digit tiered royalties based on net sales of Pfizer's products incorporating the licensed capsids.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT